In those patients with available remnant tumor samples, we explored the association between tumor immunostaining for E-cadherin and SSTR2 with sAOT results: 24 and 18 patients, respectively (15 responders and 9 non-responders for E-cadherin and 12 responders and 6 non-responders for SSTR2). Here, CDH1 is linked to neoplasm.